Takeshi Matsugi Selected Research

PhXa 85

4/2004

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Matsugi Research Topics

Disease

1	Fibrosis (Cirrhosis) 12/2018
1	Ocular Hypertension (Glaucoma, Suspect) 01/2018
1	Melanoma (Melanoma, Malignant) 04/2004
1	Experimental Melanoma 12/2003
1	Miosis 12/2003

Drug/Important Bio-Agent (IBA)

2	3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy - 1- butenyl)- 3,5- dihydroxycyclopentyl)- 5- heptenoic acid (5Z)-7-((1R,2RIBA 04/2004 - 12/2003
2	Latanoprost (Xalatan)FDA Link 04/2004 - 12/2003
2	Melanins (Melanin)IBA 04/2004 - 12/2003
2	tafluprostIBA 04/2004 - 12/2003
1	AntibodiesIBA 12/2018
1	CalciumIBA 12/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018
1	Retinaldehyde (Retinal)IBA 12/2018
1	Glial Fibrillary Acidic ProteinIBA 12/2018
1	prostaglandin F2alpha receptorIBA 04/2004
1	PhXa 85IBA 04/2004
1	3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy - 1- butenyl)- 3,5- dihydroxycyclopentyl)- 5- heptenoate 1-ethyl (5Z)-7-((1R,2RIBA 12/2003
1	Carboxylic AcidsIBA 12/2003
1	AFP-157IBA 12/2003
1	3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy - 1- butenyl)- 3,5- dihydroxycyclopentyl)- 5- heptenoate 1-methyl (5Z)-7-((1R,2RIBA 12/2003
1	EstersIBA 12/2003

Therapy/Procedure

1	Therapeutics 12/2018
1	Lasers (Laser) 01/2018